Search

Displaying results 2601 - 2610 of 2955 in total
  1. Drug

    Lurbinectedin

    go.drugbank.com/drugs/DB12674
    ApprovedInvestigational

    [A214331] On June 15, 2020, the FDA granted accelerated approval and orphan drug designation to lurbinectedin for the treatment of adult patients with metastatic SCLC who have experienced disease progression

  2. Drug

    Daptomycin

    go.drugbank.com/drugs/DB00080
    ApprovedInvestigational

    [A231379] Daptomycin was approved by the FDA on September 12, 2003, and is marketed under the name CUBICIN® by Cubist Pharmaceuticals LLC (Merck & Co.).[L32534]

  3. Drug

    Repotrectinib

    go.drugbank.com/drugs/DB16826
    ApprovedInvestigational

    [A262066] On November 15th, 2023, the FDA approved repotrectinib under the brand name Augtyro for the treatment of locally advanced or metastatic ROS1-Positive NSCLC.

  4. Drug

    Gadoquatrane

    go.drugbank.com/drugs/DB33282
    Approved

    [L63930] Bayer announced FDA approval of gadoquatrane on June 15, 2026, for use with MRI in adult and pediatric patients, including term neonates, to detect and visualize lesions with abnormal vascularity

  5. Drug

    Octreotide

    go.drugbank.com/drugs/DB00104
    ApprovedInvestigational

    On June 26, 2020, the first approved delayed-release oral somatostatin analog, Mycapssa, received FDA approval for the long term maintenance treatment of acromegaly.

  6. Drug

    Samidorphan

    go.drugbank.com/drugs/DB12543
    ApprovedInvestigational

    [A235638, A235643] Samidorphan was first approved as a variety of fixed-dose combination tablets with [olanzapine] by the FDA on May 28, 2021, and is currently marketed under the trademark LYBALVI™

  7. Drug

    Clorazepic acid

    go.drugbank.com/drugs/DB00628
    ApprovedIllicit

    In September 2020, a black box warning describing these risks was included on the product label of benzodiazepines as per FDA regulation.

  8. Drug

    Trofinetide

    go.drugbank.com/drugs/DB06045
    Approved

    [A258438] Trofinetide was approved by the FDA on March 10, 2023, for the treatment of Rett syndrome,[L45718,L45748] which is an X-linked neurodevelopmental disorder characterized by a range of cognitive

  9. Drug

    Betaine

    go.drugbank.com/drugs/DB06756
    ApprovedInvestigationalNutraceutical

    The FDA and EMA have approved the product Cystadane (betaine anhydrous, oral solution) for the treatment of homocystinuria,[L43105,L43115] and the EMA has approved the use of Amversio (betaine anhydrous

  10. Drug

    Doxorubicin

    go.drugbank.com/drugs/DB00997
    ApprovedInvestigational

    [A257614] Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin

    Products: DOXOLEM RU, DOXORUBICIN AU 2MG/ML 10MG